| Document |
Document Title |
|
WO/2002/003912A2 |
Novel C-4 substituted all-trans retinoic acid analogs are synthesized and used to treat various cancers and dermatological diseases and conditions. These novel C-4 substituted all-trans retinoic acid analogs inhibit all-trans retinoic ac...
|
|
WO/2002/004414A1 |
A compound selected from 14-O-[(Cycloalkyl-sulfanyl)acetyl]mutilins; 14-O-[Cycloalkyl-alkyl-sulfanyl)acetyl] mutilins; 14-O-[(Cycloalkoxy)acetyl] mutilins; or 14-O[(Cycloalkyl-alkoxy)acetyl] mutilins and its use as a pharmaceutical.
|
|
WO/2002/002520A2 |
The present invention is disubstituted amines of formula (I) and disubstituted amines of formula (II) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/001951A2 |
The invention relates to optically pure (-) clethodim, novel compositions of matter containing (-) clethodim substantially free from (+) clethodim, and methods of controlling vegetative growth employing such compositions.
|
|
WO/2002/002506A2 |
The present invention is substituted amines of formula (XV) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/002518A2 |
The present invention is disubstituted amines of formula (I) and disbustituted amines of formula (II) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/002522A1 |
The present invention relates to novel cyclopropane-containing diaryl sulfide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibitin...
|
|
WO/2002/002512A2 |
The present invention is substituted amines of formula (X) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/002464A2 |
A process for extracting from aqueous solution the alkali metal or ammonium salt of a phenol, naphthol, anthrol or phenanthrol or the corresponding thiol, which comprises contacting an aqueous alkaline or neutral solution of the alkali m...
|
|
WO/2002/002505A2 |
The present invention is substituted amines of formula (X) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/002515A1 |
Compounds useful in pest control, represented by the general formula [I] wherein A, B and C are each hydrogen, halogeno, trifluoro- methylsulfonyloxy, alkyl, alkylthioalkyl, or the like; X is a single bond, methylene, ethylene, or the li...
|
|
WO/2002/002507A1 |
The invention relates to an oxidative colouring agent for keratin fibres, in particular hair, based on a developing agent-coupling agent combination, which contains as a developing agent, at least one 2-hydroxy-5-amino-biphenyl derivativ...
|
|
WO/2002/000612A1 |
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or preventio...
|
|
WO/2002/000167A2 |
In accordance with the present invention, there are provided modified forms of nonsteroidal anti-inflammatory drugs (NSAIDs). Modified NSAIDs according to the invention provide a new class of anti-inflammatory agent which provides the th...
|
|
WO/2002/000606A1 |
A novel biphenyl compound having GPR14 antagonism. It is a compound represented by the formula (I) or a salt thereof, wherein R?1¿ represents hydrogen, etc.; X represents 1 to 12 spacers; A represents amino, etc.; R?2¿ and R?3¿ each r...
|
|
WO/2002/000607A1 |
Amide compounds represented by the following general formula; and microbicides containing the same as the active ingredient: wherein R?1¿ is C¿1-10? haloalkyl or the like; R?2¿ is hydrogen or the like; X is oxygen or sulfur; Y is oxyg...
|
|
WO/2001/098251A1 |
New compounds of formula (I) are described: The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.
|
|
WO/2001/096285A1 |
The present invention relates to compound of formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿ and n are as defined in the description and claims and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof...
|
|
WO/2001/096348A1 |
3-Substituted benzotrifluorides are selectively deprotonated and functionalized in the 2-position. The selectively is achieved by equilibrating the mixture of lithiobenzotrifluorides initially formed in the presence of a primary or secon...
|
|
WO/2001/096292A1 |
A calixarene dimer of the general formula (I-G), comprising a first calixarene moiety I and a second calixarene moiety G, wherein: L is [ - CH¿2? -] or [ -O-CH¿2?-O- ] and is the same or different between each aryl group; R?5¿ is H, N...
|
|
WO/2001/096291A1 |
The present invention is directed to multireactivity polymercaptans, star-shaped copolymers and methods of preparing wherein the polymer comprises a polyvalent mercaptan core and three or more polymeric arms which extend radially from th...
|
|
WO/2001/096263A1 |
A process for the production of fluorinated organic compounds, characterized by fluorinating an organic compound bearing a hydrogen atom with IF¿5?; and a novel fluorination process of fluorinating an organic compound bearing a hydrogen...
|
|
WO/2001/092201A1 |
Novel substituted phenylpropionic acid derivatives of the general formula (1), which bind to human peroxisome proliferator activated receptor $g(a) (PPAR$g(a)) as ligand to activate the receptor and thereby exhibit a potent lipid-decreas...
|
|
WO/2001/092274A2 |
The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
|
|
WO/2001/092273A2 |
New benzenedicarboxylic acid derivative compounds; pharmaceutical compositions, diagnostic methods, and diagnostic kits that include those compounds; and methods of using those compounds for inhibiting NAALADase enzyme activity, detectin...
|
|
WO/2001/092218A2 |
Novel 'bispolyamine' inhibitor compounds of polyamine transport are disclosed. These compounds are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins,...
|
|
WO/2001/090716A2 |
This invention generally relates to nanocrystal compounds, and linker arm for nanocrystal compounds that attach the nanocrystals to the organic compounds. The nanocrystal compound comprises a nanocrystal, linker arm, and organic compound...
|
|
WO/2001/090717A2 |
This invention generally relates to nanocrystal compounds, and linker arm for nanocrystal compounds that attach the nanocrystals to the organic compounds. The nanocrystal compound comprises a nanocrystal, linker arm, and organic compound...
|
|
WO/2001/090100A1 |
Compounds of formula (I): R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R?1¿ is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.
|
|
WO/2001/090060A1 |
Diphenyl disulfide derivatives of formula (I) wherein X is -NHC(=O)NH-R and R is as defined in the claims are useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and pr...
|
|
WO/2001/090059A1 |
Methods and compositions for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The compositions...
|
|
WO/2001/087840A1 |
Novel propanoic acid derivatives are integrin receptor antagonists or inhibitors, in particular of the avb3 integrin receptor. The compounds of the invention are for instance useful for the treatment of solid tumors by inhibition of angi...
|
|
WO/2001/087829A1 |
The invention relates to bisacylguanidine of formula (I), wherein one of radicals is R?1¿, R?2¿, R?3¿, R?4¿, or R?5¿ and one of the radicals is R?6¿, R?7¿, R?8¿, R?9¿ or R?10¿, and to its physiologically acceptable salts and/or...
|
|
WO/2001/087996A2 |
This invention is directed to a catalyst and an associated process for polymerizing olefins or olefin-containing compounds, to corresponding olefin polymers, to derivatives of the olefin polymers, and to lubricant and fuel compositions t...
|
|
WO/2001/087822A1 |
The invention relates to phenyl-propargylether derivatives of general formula (I) including the optical isomers thereof and mixtures of such isomers, wherein R¿1? is hydrogen, alkyl, cycloalkyl or optionally substituted aryl, R¿2? and ...
|
|
WO/2001/087830A2 |
The present application is directed to chemical compounds of formula (I-A) or formula (II-A) (in which the variables are as defined in the claims), compositions containing them and uses of the compositions for treating sleepiness, tiredn...
|
|
WO/2001/083436A2 |
The present invention relates to compounds of formula (I) (where the variables R¿A?, R¿B?, R¿C? and n are as defined in the claims) and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic tre...
|
|
WO/2001/083431A1 |
Compounds of the general formula (I), optical isomers or prodrugs of the same, pharmaceutically acceptable salts of them, or solvates thereof: (I) wherein R?1¿ is hydroxyl or the like; R?2¿ is optionally substituted lower alkyl or the ...
|
|
WO/2001/083434A2 |
This invention relates to anti-inflammatory and analgesic compounds, especially to certain p-(sulfonyl)phenyl amino derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compound...
|
|
WO/2001/083421A1 |
A process for the preparation of 2-halobenzoic acids of the general formula (I), characterized by reacting a benzoic acid of the general formula (II) with a halogenating agent in the presence of a Pd catalyst. [In the formulae, A is -OH,...
|
|
WO/2001/083438A2 |
New RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification, and pharmaceutically active salts of carboxylic acids of formula (I), further the invention relates to the use of such retinoic a...
|
|
WO/2001/081333A2 |
A novel process for preparing 3,4-di(carbocyclyl or heterocyclyl)thiophenes comprising reacting a compound of Formula IV with a ring cyclizing reagent to form the compound of Formula V to yield a compound of Formula V wherein R?1¿, R?2Â...
|
|
WO/2001/081299A1 |
A process for producing a bishalophenyl disulfide, characterized by reacting a halothiophenol with an alkali metal hydroxide to obtain an alkali metal halothiophenolate and subsequently converting the halothiophenolate into a disulfide w...
|
|
WO/2001/081295A1 |
Described are compounds of Formula I and Formula II and their pharmaceutically acceptable salts. The compounds of Formulas I and II are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such a...
|
|
WO/2001/081365A2 |
A metal chelating composition having the formula: wherein Q is a carrier; S?1¿ is a spacer; L is -A-T-CH(X)- or -C(&equals O)-; A is an ether, thioether, selenoether, or amide linkage; T is a bond or substituted or unsubstituted alkyl o...
|
|
WO/2001/081332A2 |
Methods of treating cyclooxygenase-2 mediated disorders comprising administering to a subject a therapeutically effective amount of one or more 2-fluorobenzenesulfonyl compounds corresponding to Formula (I) wherein A, R?1¿, R?2¿, and R...
|
|
WO/2001/079157A1 |
Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
|
|
WO/2001/078712A1 |
Styryl benzylsulfones of formula (I) are useful as antiproliferative agents, including, for example, anticancer agents. In said formula, (a) (i) at least three of R¿1?, R¿2?, R¿3?, R¿4? and R¿5? are independently selected from the g...
|
|
WO/2001/078723A1 |
Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinophathy, rheumatoid arthritis...
|
|
WO/2001/077072A2 |
It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) in...
|
